With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...

In a video Karsanbhai Patel of the Nirma group is purportedly heard saying that only those who led the protests reaped ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

The doctor would use AXS-05 just long enough to control patients’ agitation, the firm adds. It keeps an Outperform rating on Axsome with a $140 price target Published first on TheFly – the ...

Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of agitation in ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the ...